Semma Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Semma Therapeutics's estimated annual revenue is currently $12.9M per year.
- Semma Therapeutics received $114.0M in venture funding in November 2017. 0
- Semma Therapeutics's total funding is $163M.
Semma Therapeutics Competitors & AlternativesAdd Company
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Semma Therapeutics?
Semma Therapeutics is pioneering the new treatment paradigm of using cells as medicine. Semma's new class of regenerative medicine therapies couples its breakthrough stem cell technologies with proprietary delivery systems designed to protect cells from the immune system. Ongoing research at Semma Therapeutics is focused on combining these highly-differentiated active cells with a state-of-the-art device to provide a functional cure for patients with diabetes. Semma Therapeutics is working to bring new therapeutic options to the clinic and improve the lives of patients. The company is headquartered in Cambridge, MA, with operations in Providence, RI. For more information, visit www.semma-tx.com.keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
Semma Therapeutics News
... Eli Lilly and Sigilon, Novo Nordisk, Semma Therapeutics, evotec, Living Cell Technologies Limited, Neurotech Pharmaceuticals, Inc.,...
For Melton, joining Vertex is something of a homecoming. Earlier in his career, he co-founded diabetes-focused Semma Therapeutics, which was...
Doug Melton to reunite with his Semma collaborators at Vertex to develop 'curative cell therapies'. Kyle LaHucik. Associate Editor. A reunion is happening at...
Vertex Pharmaceuticals plans to lay out $950 million in cash to buy Semma Therapeutics, a biotech company pursuing treatments for type 1 ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Semma Therapeutics Funding
|2017-03-23||$Undisclosed||Undisclosed||JDRF T1D Fund||Article|
|2017-11-30||$114.0M||Undisclosed||Eight Roads Ventures||Article|